Charcot neuro-osteoarthropathy (CNO), often called Charcot foot, is a progressive, non-infectious destruction of the bones and joints of the foot and ankle that occurs in people with peripheral neuropathy — most often as a complication of long-standing diabetes mellitus. Although uncommon, the condition is consequential: untreated or late-recognized CNO can result in profound deformity, plantar ulceration, osteomyelitis, and lower-limb amputation. The 2023 release of the first dedicated International Working Group on the Diabetic Foot (IWGDF) guideline on active CNO has reframed how clinicians should approach diagnosis, immobilization, and monitoring.
Why Charcot Foot Matters
Population studies estimate the prevalence of Charcot foot in people with diabetes at roughly 0.1% to 0.6%, rising to several percent in high-risk specialty foot clinics. A 2022 meta-analysis of 16 studies (2,250 patients) reported an overall amputation frequency of 15% in patients with diabetic Charcot arthropathy — 9% major and 5% minor — with a 5-year mortality of approximately 24.5% (Svendsen et al., Foot and Ankle Surgery, 2022). These figures place CNO alongside diabetic foot ulceration as a leading cause of preventable lower-limb loss.
Recognizing Active Disease Early
Active CNO classically presents as a warm, swollen, erythematous foot in a person with peripheral neuropathy, often without significant pain and frequently without a clear history of trauma. Because the early picture mimics cellulitis, deep vein thrombosis, gout, or osteomyelitis, misdiagnosis is common — and the cost of delay is high. The IWGDF 2023 guideline emphasizes that when active CNO is suspected, knee-high immobilization should be initiated promptly while diagnostic workup proceeds, rather than waiting for confirmation (Wukich et al., Diabetes/Metabolism Research and Reviews, 2024).
The Role of Temperature Monitoring
Skin temperature asymmetry is one of the most useful bedside signs. A difference of 2°C or more between the affected foot and the contralateral foot at the site of maximum deformity supports active disease, and the magnitude of the gradient correlates with disease activity. Serial temperature measurements are also used to track resolution: as the differential narrows toward baseline, the disease is moving toward remission.
Imaging: When Plain Films Are Not Enough
Plain radiographs remain the first-line image, but in early (Eichenholtz stage 0) disease, X-rays are typically normal even when bone marrow edema, microfractures, and joint subluxation are already present. MRI is the most sensitive modality for early CNO and is recommended whenever radiographs are unrevealing in a clinically suspicious foot. A 2024 retrospective audit found that patients diagnosed by MRI presented at stage 0, while those diagnosed by X-ray had progressed to stage 1, supporting earlier intervention when MRI is used. The IWGDF further notes that inflammatory markers such as CRP, ESR, and white blood cell count should not be used to diagnose or exclude CNO with intact skin, as they lack adequate specificity.
Treatment: Immobilization Remains the Cornerstone
The therapeutic backbone of active CNO is sustained offloading and immobilization until bone activity has resolved. The IWGDF 2023 guideline articulates a clear hierarchy of devices. The total contact cast (TCC) is recommended as first-line treatment, providing the most effective combination of immobilization and pressure redistribution. A non-removable knee-high walker is the second choice when a TCC is not feasible. A removable knee-high device worn at all times is reserved as a third option for patients who cannot tolerate or have contraindications to non-removable devices. Below-the-ankle devices — surgical shoes, postoperative sandals, and slipper casts — are explicitly not recommended, because they fail to immobilize the affected joints adequately. Most patients require several months of continuous offloading before clinical signs resolve and fractures consolidate.
Determining Remission
Transition out of immobilization is guided by both clinical and imaging criteria: resolution of edema and erythema, normalization of the skin temperature differential, and radiographic or MRI evidence of consolidation. Pilot work using serial non-contrast MRI (the CADOM feasibility study, Gooday et al., Journal of Foot and Ankle Research, 2023) suggests that imaging-guided monitoring may shorten total immobilization time, though larger trials are still needed.
Surgery and Long-Term Prevention
Reconstructive surgery is generally reserved for patients with unstable deformities, recurrent ulceration over bony prominences, or failure of conservative management. A 2024 evidence-based algorithm in Frontiers in Clinical Diabetes and Healthcare emphasizes timing surgery only after the acute inflammatory phase has resolved, when feasible, to reduce hardware failure and infection risk. Once remission is achieved, lifelong attention to footwear, custom orthoses, glycemic control, and skin temperature self-monitoring is essential to prevent re-activation, which can occur in either foot.
Clinical Takeaways
Charcot neuro-osteoarthropathy is uncommon but disabling. Early recognition rests on a high index of suspicion in any neuropathic patient with a warm, swollen foot, supported by temperature asymmetry and MRI when radiographs are normal. Treatment is anchored in prompt, sustained, knee-high offloading — preferably a total contact cast — with surgical reconstruction reserved for selected patients. The 2023 IWGDF guideline provides the most current evidence-based framework for limb preservation in this population.
References
- Wukich DK, Raspovic KM, Hobizal KB, et al. Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023). Diabetes/Metabolism Research and Reviews. 2024;40(3):e3646.
- Raspovic KM, Hobizal KB, Rogers LC, et al. Diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus: a systematic review. Diabetes/Metabolism Research and Reviews. 2024;40(3):e3653.
- Svendsen OL, Rabe OC, Winther-Jensen M, Allin KH, Jansen RB. Amputation and mortality frequencies associated with diabetic Charcot foot arthropathy: a meta-analysis. Foot and Ankle Surgery. 2022;28(8):1297–1304.
- Gooday C, Game F, Woodburn J, et al. A randomised feasibility study of serial magnetic resonance imaging to reduce treatment times in Charcot neuroarthropathy in people with diabetes (CADOM). Journal of Foot and Ankle Research. 2023;16:5.
- Schmidt BM, Holmes CM. Charcot neuro-osteoarthropathy: a review of key concepts and an evidence-based surgical management algorithm. Frontiers in Clinical Diabetes and Healthcare. 2024;5:1344359.
Comments
